Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer (Q39591068)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 July 2016

Language	Label	Description	Also known as
English	Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer	scientific article published on 18 July 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Sung-Bae Kim

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Hans Wildiers

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Ian E Krop

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Melanie Smitt

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Ron Yu

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sanne Lysbet de Haas

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Antonio Gonzalez-Martin

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

0 references

publication date

18 July 2016

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

139

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

2336-2342

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

Downstream signalling events regulated by phosphatidylinositol 3-kinase activity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

Signaling by distinct classes of phosphoinositide 3-kinases

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30276

21 January 2018

Identifiers

10.1002/IJC.30276

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39591068&oldid=1842537811"